FATE Stock Summary and Trading Ideas (Fate Therapeutics | NASDAQ:FATE)

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

Fate Therapeutics trades on the NASDAQ stock market under the symbol FATE.

As of November 6, 2026, FATE stock price declined to $1.84 with 1,820,139 million shares trading.

FATE has a beta of 4.39, meaning it tends to be more sensitive to market movements. FATE has a correlation of 0.23 to the broad based SPY ETF.

FATE has a market cap of $219.87 million. This is considered a Small Cap stock.

Last quarter Fate Therapeutics reported $0 in Revenue and -$.25 earnings per share. This fell short of revenue expectation by $-1 million and exceeded earnings estimates by $.01.

In the last 3 years, FATE traded as high as $8.83 and as low as $.66.

The top ETF exchange traded funds that FATE belongs to (by Net Assets): VTI, VXF, SCHA, VHT, IWC.

FATE has outperformed the market in the last year with a return of +68.3%, while the SPY ETF gained +9.6%. However, in the most recent history, FATE shares have underperformed the stock market with its stock returning -29.4% in the last 3 month period and -12.2% for the last 2 week period, while SPY has returned -4.2% and -3.8%, respectively.

FATE support price is $1.77 and resistance is $1.93 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that FATE shares will trade within this expected range on the day.